The vice-president of a diabetes charity has been called on to sever ties with the group because he also acts as a lobbyist for a drugs giant. Sir Michael Hirst is both a figurehead for Diabetes UK and an adviser to Denmark-based Novo Nordisk, a firm that is planning to withdraw a vital form of insulin from the UK.Novo Nordisk plans to remove Mixtard 30 as a treatment, which some diabetics have used for more than 10 years. Doctors believe the move could cause problems for sufferers and the NHS.
Hirst, a one-time Tory MP, is a former chair of Diabetes UK and now acts as the charity's vice-president. At the same time, he is chair of Edinburgh-based Pagoda PR, which represents Novo Nordisk.Hirst is “retained to act for a number of health-related clients, including Roche Diagnostics and Novo Nordisk”. Services include public affairs advice and parliamentary lobbying.
Tristan Stewart-Robertson, a writer and type-1 diabetic, said: “The withdrawal of this form of insulin highlights the problem of having only two companies worldwide that produce insulin. With only two firms controlling the patent, you really need a patients’ rights group that is 100% on the diabetics’ side."
When Novo Nordisk withdrew another insulin treatment, Actrapid in 2005 Hirst said: “...product rationalisation is a common fact of life.”
A myth pervades that 1917 was a 'socialist' revolution rather it was the continuation of the capitalist one. What justification...
The Socialist Party insist the working class is the only social force capable of putting an end to capitalism—the root cause of econom...
The life expectancy of people born in many parts of Scotland has fallen, as health chiefs continue to be worried about the worsening figu...